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Eﬀ ects of antenatal multiple micronutrient 
supplementation on children’s weight and size at 2 years of 
age in Nepal: follow-up of a double-blind randomised 
controlled trial
Anjana Vaidya, Naomi Saville, Bhim Prasad Shrestha, Anthony M de L Costello, Dharma S Manandhar, David Osrin
Summary
Background The negative eﬀ ects of low birthweight on the later health of children in developing countries have been 
well studied. However, undertaking programmes to address this issue can be diﬃ  cult since there is no simple 
correlation between increasing birthweight and improving child health. In 2005, we published results of a randomised 
controlled trial in Nepal, in which 1200 women received either iron and folic acid or a supplement that provided the 
recommended daily allowance of 15 vitamins and minerals, over the second and third trimesters of pregnancy. Here, 
we report on 2–3 years’ follow-up of children born during the trial.
Methods We visited children at home and obtained data for the primary outcomes of weight and height, for childhood 
illnesses, and maternal blood haemoglobin. The study is registered as an International Standard Randomised 
Controlled Trial, number ISRCTN88625934.
Findings Between December, 2005, and December, 2006, we assessed 917 children (455 controls, 462 intervention) at 
a mean age of 2·5 years. Mean birthweight had been 77 g (95% CI 24–130) greater in the micronutrient group than in 
controls. At 2·5 years old, controls weighed a mean of 10·7 kg (SD 1·38), and those in the intervention group 10·9 kg 
(SD 1·54). Children of women who had taken multiple micronutrient supplements during pregnancy were a 
mean 204 g (95% CI 27–381) heavier than controls. They also had greater measurements than controls in the 
circumference of the head (2·4 mm [95% CI 0·6–4·3]), chest (3·2 mm [0·4–6·0]), and mid-upper arm (2·4 mm 
[1·1–3·7]), and in triceps skinfold thickness (2·0 mm [0·0–0·4]). Systolic blood pressure was slightly lower in the 
intervention group (2·5 mm Hg [0·5–4·6]).
Interpretation In a poor population, the eﬀ ects of maternal multiple micronutrient supplementation on the fetus 
persisted into childhood, with increases in both weight and body size. These increases were small, however, since 
those exposed to micronutrients had an average of 2% higher weight than controls. The public-health implications of 
changes in weight and blood pressure need to be clariﬁ ed through further follow-up.
Introduction
The negative eﬀ ects of a birthweight of less than 2500 g 
on child morbidity and survival in developing countries 
have been well described.1–3 What is less clear is what 
eﬀ ect interventions to raise birthweight might have on 
child health. Health strategies have generally been based 
on the observation that in poor countries, low birthweight 
is more common in babies who are born at full term than 
in those born prematurely,4 and that low birthweight 
might lead to childhood malnutrition.
Creating public-health programmes to tackle this issue 
has been diﬃ  cult, however, for three reasons. First, we 
have not yet managed to get potential interventions to 
women at risk, at a time of life when they might be helpful, 
and at a population level.5 Second, increased birthweight is 
not necessarily followed by increased survival and reduc-
tions in morbidity in either newborn babies or children—
children with similar weights could diﬀ er in mortality rates 
between populations.6 Third, possible associations between 
fetal and infant growth and adult disease have made us 
cautious about increasing infant weight.7
In 2005, we published the results of an individually 
randomised, double-blind controlled trial in Dhanusha 
district, Nepal.8 1200 women received either routine 
iron and folic acid supplements or a multiple 
micronutrient supplement providing the recommended 
daily allowance of 15 vitamins and minerals, over the 
second and third trimesters of pregnancy. Mean 
birthweights were 2733 g (SD 422) in the control group 
and 2810 g (SD 453) in the intervention group, 
representing a diﬀ erence of 77 g (95% CI 24–130) and a 
25% fall in the proportion of low birthweight infants. 
The groups did not diﬀ er in the duration of gestation, 
infant length, or head circumference.
Nine trials of similar supplementation approaches are 
being systematically reviewed.8–18 Antenatal multiple 
micronutrient supplementation probably does increase 
birthweight, but whether this translates into short-term 
or long-term health beneﬁ ts remains uncertain. Impor-
tant questions include whether the eﬀ ects of antepartum 
intervention are sustained, and whether micronutrient 
repletion improves early childhood growth in a way that 
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could confer lasting beneﬁ t. To answer these questions, 
we undertook a follow-up of children born in the original 
trial, at the age of 2–3 years.
Methods
Participants
In the original trial, we enrolled 1200 participants from 
an antenatal clinic at Janakpur zonal hospital, in Nepal’s 
Dhanusha district. The inclusion criteria were gestation 
of up to 20 completed weeks, based on dates and 
ultrasound biometry; singleton pregnancy; no notable 
fetal abnormality on obstetric ultrasound; no existing 
maternal illness of a severity that could compromise the 
outcome of the pregnancy; and accessibility for follow-up 
at home.
After providing signed consent, participants received 
supplements from enrolment (at no earlier than 
12 weeks’ gestation) to delivery. The daily micronutrient 
supplements were provided in monthly allocations. 
Participants were followed up every 2 weeks, at birth, 
and at 1 month postpartum. Anthropometric measures 
were recorded within 72 h of birth. Allocation was 
double-blind and randomised to two groups of 600 
participants. The control group received tablets 
containing iron (60 mg) and folic acid (400 µg). The 
intervention group received tablets containing vitamin A 
(800 µg), vitamin E (10 mg), vitamin D (5 µg), vitamin B1 
(1·4 mg), vitamin B2 (1·4 mg), niacin (18 mg), vitamin B6 
(1·9 mg), vitamin B12 (2·6 µg), folic acid (400 µg), 
vitamin C (70 mg), iron (30 mg), zinc (15 mg), 
copper (2 mg), selenium (65 µg), and iodine (150 µg).19 
All supplements were manufactured by Danish 
Pharmaceutical Industries Ltd (Ballerup, Denmark).
The trial was approved by the Nepal Health Research 
Council, and by the ethics committee of the Institute 
of Child Health and Great Ormond Street Hospital 
for Children, UK, and was undertaken in collabora-
tion with the Nepal Government Ministry of Health. 
Bene ﬁ ts to participants included the supply of supple-
ments, free healthcare, and expedited referral in the 
event of complications. Information provided by partici-
pants remained conﬁ dential. Access was restricted 
to supervisory and research staﬀ  at the analytical level. 
No analyses or outputs included the names of 
participants.
Procedures
Children born in the trial were followed-up at 2·5 years 
of age by ﬁ ve ﬁ eld workers, one of whom acted as 
coordinator. Training in anthropometric techniques 
included taking test measurements of 300 children who 
were not in the trial. We were particularly keen to keep 
variation between observers to a minimum since, for 
example, it accounted for 23% of the variation in head 
circumference, whereas intra-observer variation 
accounted for 8%. Final study measurements were 
therefore restricted to two ﬁ eld workers.
Visiting schedules were set according to the ages of 
individual children and the need to cover ﬂ ood-prone 
areas outside the monsoon season. All participants who 
had not moved home too far for us to travel to were 
visited at home up to ﬁ ve times. The ﬁ eld workers were 
unaware of the initial supplement allocation since access 
to the codes was restricted to principal investigators. We 
obtained additional informed verbal consent from 
mothers and family members to collect follow-up 
information and measurements. Participants received a 
towel and a sweet as a token of appreciation.
Primary outcomes were weight and height. Weight was 
measured with Seca 835 electronic scales (Hamburg, 
Germany) accurate to 10 g. Standing height was measured 
with a portable Leicester stadiometer accurate to 1 mm, 
barefoot and with the head in the auriculo-orbital plane. 
Secondary outcomes included circumferences of the 
head, chest, waist, hip, and mid-upper arm, triceps 
skinfold thickness, and blood pressure.
We also obtained information on childhood illnesses 
and measured maternal blood haemoglobin. Head and 
mid-upper arm circumferences were measured with 
disposable insertion tapes accurate to 1 mm (Harlow 
1985 women screened for eligibility
785 did not meet inclusion criteria
1200 randomised
600 allocated to control group
20 lost to follow-up
      12 could not be found
        8 moved beyond study
12 discontinued trial
      5 lost to miscarriage
      7 withdrew from trial
19 lost to follow-up
        8 could not be found
      11 moved beyond study
10 discontinued trial
      2 lost to miscarriage
      7 withdrew from trial
      1 clinical problems
568 delivered
   18 stillbirth
   12 neonatal death
571 delivered
   15 stillbirth
   17 neonatal death
539 for potential follow-up538 for potential follow-up
455 for anthropometric 
         measurements at >2 years
462 for anthropometric 
         measurements at >2 years
75 lost to follow-up
  8 post-neonatal deaths
     6 deaths at <1 year
     2 deaths at >1 year
72 lost to follow-up
     5 post-neonatal deaths
        4 deaths at <1 year
        1 death at >1 year
600 allocated to intervention group
Figure: Trial proﬁ le
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Printing Ltd, South Shields, Tyne and Wear, UK). Head 
circumference was taken at the maximum occipito-frontal 
measurement. Upper arm circumference was measured 
midway between the tip of the olecranon process and 
the acromion process. Chest, waist, and hip 
circumferences were measured with a plastic measuring 
tape accurate to 1 mm. The chest was measured at the 
level of the nipples, midway between inspiration and 
expiration during quiet breathing. Waist circumference 
was measured at the level of the natural waist, and the 
hip at the level of maximum circumference over the 
buttocks. Triceps skinfold thickness was measured with 
Harpenden callipers accurate to 1 mm (Assist Creative 
Resource, Wrexham, UK). The measurement was taken 
midway between the tip of the olecranon process and 
the acromion process, in the midline of the posterior 
surface of the extended dominant arm. All measurements 
except weight and height were made three times and the 
middle value recorded for analysis.
Blood pressure was measured with the child on her 
mother’s lap, with a portable CE0 197 Omron electronic 
sphygmomanometer (Japan). We measured maternal 
haemoglobin with a spectrophotometer on ﬁ nger-prick 
blood samples using a portable HemoCue AB CE201 
(Dronﬁ eld, UK), with daily calibration checks. We 
collected information about the number of illnesses in 
the ﬁ rst year of life and about speciﬁ c illnesses in the 
14 days preceding the interview. Medical reports were 
examined where available and verbal autopsy 
questionnaires were completed in the event of death. 
We deﬁ ned loss-to-follow-up as conﬁ rmed information 
that a participant had moved beyond the possibility of 
visiting, usually to India. Information about participants, 
their progress, and outcomes, was collected in individual 
ﬁ les which were manually checked for completeness. 
Data were entered into a relational database 
management system with ﬁ eld validity rules (FileMaker 
Pro 5.5, USA).
Statistical analysis
The original trial sample size was computed to detect a 
diﬀ erence in mean birthweight of 100 g at a power 
of 90% and a two-sided signiﬁ cance level of 0·05, 
allowing for 30% loss-to-follow-up. The power of the 
study would be 81% if the true diﬀ erence were equal to 
the 77 g diﬀ erence observed. We assessed outliers in 
Data Desk 6.2.1 (Ithaca, NY). The rest of the analysis was 
done in the Statistical Program for the Social Sciences 
version 11 (SPSS Inc, USA). Baseline confounders were 
assessed by inspecting proportions for categorical 
variables and means for continuous variables. 
Continuous anthropometric outcomes were compared 
ﬁ rst through t tests and univariate regression, and then 
adjusted for potential confounding with multivariate 
linear regression models. Total upper arm area was 
estimated as the square of the circumference divided 
by 4π.20 Upper-arm fat area was calculated as 
circumference multiplied by triceps skinfold thickness, 
and then divided by two, a model reported as consistent 
with magnetic resonance images.21
Role of the funding source
The original study was funded by The Wellcome Trust. 
The follow-up study was funded by a grant from an 
anonymous charitable donor. Neither played a part in the 
study design; the collection, analysis, or interpretation of 
data; the writing of the report; or the decision to submit 
the paper for publication.
Results
The ﬁ gure shows the trial proﬁ le. We visited 917 mothers 
and children from December, 2005, to December, 2006: 
455 in the control group and 462 in the intervention 
group. Retention rates in the control and intervention 
groups (taking into account discontinuation in the study, 
fetal loss, stillbirths, infant deaths, post-infancy deaths 
Control 
(n=455)
Intervention 
(n=462)
Lost–to–follow up 
(n=147)
Location
Urban 227 (49·9%) 231 (50·0%) 96 (65·3%)
Rural 228 (50·1%) 231 (50·0%) 51 (34·7%)
Land owned
None 22 (4·8%) 23 (5·0%) 11 (7·5%)
<10 kattha (0·3 hectares) 241 (53·0%) 267 (57·8%) 81 (55·1%)
>10 kattha 192 (42·2%) 172 (37·2%) 55 (37·4%)
Husband’s occupation
No work 53 (11·7%) 51 (11·0%) 16 (10·9%)
Farming 71 (15·6%) 68 (14·7%) 19 (12·9%)
Salaried 181 (39·8%) 203 (43·9%) 71 (48·3%)
Small business 83 (18·2%) 84 (18·2%) 32 (21·7%)
Waged labour 53 (11·7%) 45 (9·8%) 5 (3·4%)
Student 7 (1·5%) 5 (1·1%) 2 (1·4%)
Out of country 7 (1·5%) 6 (1·3%) 2 (1·4%)
Consumer durables
Motor vehicle, television, or refrigerator 243 (53·4%) 239 (51·5%) 78 (53·1%)
Sewing machine, cassette player, camera, fan, 
or bullock cart
26 (5·7%) 18 (3·9%) 5 (3·4%)
Clock, radio, iron, or bicycle 122 (26·8%) 133 (28·8%) 42 (28·5%)
None of the above 64 (14·1%) 73 (15·8%) 22 (15·0%)
Schooling
None 212 (46·6%) 219 (47·4%) 45 (30·6%)
Primary 40 (8·8%) 39 (8·4%) 21 (14·3%)
Lower secondary or higher 203 (44·6%) 204 (44·2%) 81 (55·1%)
Parity at birth of index child
0 217 (47·7%) 223 (48·3%) 71 (48·3%)
1 135 (29·7%) 130 (28·1%) 41 (27·9%)
2 65 (14·3%) 63 (13·6%) 23 (15·6%)
3 26 (5·7%) 32 (6·9%) 9 (6·1%)
4 10 (2·2%) 9 (2·0%) 1 (0·7%)
≥5 2 (0·4%) 5 (1·1%) 2 (1·4%)
Table 1: Household and participant characteristics at enrolment
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and losses-to-follow-up) were 76% and 77%, respectively. 
Retention rates in children who could potentially have 
been followed up after the neonatal period were 85% 
and 86%, respectively.
At follow-up, we identiﬁ ed a neonatal death in the 
control group that we could not have noted in the ﬁ rst 
phase. This changed the neonatal mortality rate in the 
control group (quoted in the original paper as 20·0)8,22 
to 21·8 (95% CI 11·3–37·8) per 1000 livebirths. The rate 
in the intervention group remains the same as the initial 
report, at 30·6 (17·9–48·5). We identiﬁ ed six 
post-neonatal infant deaths in the control group and 
four in the intervention group. Infant mortality rates 
(deaths at younger than 1 year, with a denominator of 
livebirths minus losses-to-follow-up) were 37·9 
(22·6–59·2) per thousand livebirths in the control 
and 43·4 (27·1–65·6) in the intervention group. Post-
neonatal deaths were ascribed to pneumonia (two), 
diarrhoea (two), meningitis (one), convulsion (two), 
measles followed by conﬁ rmed tuberculosis (one), a 
hepatic syndrome (one), complications of cleft palate 
(one), a bleeding disorder (one), and sudden unexplained 
death overnight (two). Four mothers had died between 
the postnatal period and follow-up, of burns, pesticide 
ingestion, head injury after a fall, and a possible 
haematological malignancy.
Table 1 compares household and participant 
characteristics at enrolment in the two groups, and in 
the 147 participants who were lost-to-follow-up at 2 years. 
Investigation suggests that potential confounders were 
evenly allocated. Compared with the retained individuals, 
women lost-to-follow-up were more likely to be urban, 
have husbands who were salaried or ran small 
businesses, and have gone to school. They were less 
likely to own land and have husbands who worked in 
agriculture or as waged labourers.
Table 2 compares maternal and child characteristics 
between the groups at follow-up. 43% of women were 
anaemic. 42% had blood haemoglobin levels below 
6·8 mmol/L and 1% below 4·3 mmol/L. Just under half 
of participants had been primigravid in the trial and 
there were no signiﬁ cant diﬀ erences between maternal 
anthropometric ﬁ ndings. 94% of infants had been 
breastfed. The mean ages of introduction of other 
liquids, cow’s milk, or regular solids did not diﬀ er 
between the allocation groups. Reported morbidity was 
common: 35% of children were described as having had 
fever, and 36% as having had a cough, in the fortnight 
before the interview. We identiﬁ ed no diﬀ erence between 
the groups in reports of illness in either the previous 
14 days or the ﬁ rst year of life. Immunisation levels were 
equivalent and high, with reporting of over 90% for BCG 
(Bacille Calmette Guérin) vaccine, 99% for oral polio 
vaccine and DPT (diphtheria, pertussis, and tetanus) 1-3, 
and 98% for measles. The most recent inclusion in the 
schedule—hepatitis B immunisation—was reported at 
rates of over 93% for all three doses.
For children who were followed up, mean gestation at 
birth was 39·38 (SD 1·70) weeks in the control group 
and 39·58 (1·57) in the intervention group. 468 (51·0%) 
were boys and 449 (49·0%) girls. This distribution did 
not diﬀ er between either allocation or loss-to-follow-up. 
Mean age at follow-up was 2·56 (SD 0·35; 
range 1·98–3·63) years in the control group and 2·56 
(0·35, 1·98–3·85) in the intervention group. Table 3 
shows the anthropometric ﬁ ndings and summarises four 
analyses: (1) unadjusted analysis comparing mean 
measures between the groups; (2) analysis adjusted for 
the ages of children when the measurements were made; 
(3) analysis adjusted for age, and also for sex, maternal 
parity, and gestation at birth—this is an intuitive approach 
similar to that used in a study from India;23 and (4) analysis 
based on a parsimonious model adjusted for age, sex, 
gestation at birth, maternal weight at enrolment, and 
maternal education. We used single variables to describe 
maternal size and social status, on the basis of signiﬁ cance 
and greatest explanatory eﬀ ect in univariate analysis. The 
model accounts for 28% of the variance in child weight at 
follow-up. Tables 1 and 2 suggest that randomisation 
dealt with potentially uneven distribution of confounders, 
and the outcomes appear robust to adjustment. Thus, we 
will discuss the ﬁ ndings as they are presented after 
adjustment for age at follow-up.
The mean weight was 10·7 kg (SD 1·38) in the control 
group and 10·9 kg (SD 1·54) in the intervention group. 
Children of women who had taken multiple micronutrient 
Control Intervention
Mothers
Age (years) 24·5 (3·4) [n=455] 24·6 (3·5) [n=452]
Weight (kg) 45·8 (7·3) [n=452] 45·8 (7·4) [n=457]
Height (m) 1·51 (0·54) [n=452] 1·50 (0·57) [n=455]
Body-mass index (kg/m²) 20·4 (5·0) [n=452] 20·4 (2·9) [n=455]
Haemoglobin (mmol/L) 6·98 (0·79) [n=452] 6·96 (0·83) [n=456]
Had another pregnancy since the trial pregnancy 159 (34·9%) [n=455] 155 (33·5%) [n=462]
Age of infant from subsequent pregnancy in weeks 29·1 (18·4) [n=455] 31·7 (21·3) [n=462]
Children
Breastfed 432 (94·9%) [n=455] 433 (93·7%) [n=462]
Age at introduction of other liquids (months) 4·04 (2·62) [n=455] 4·04 (2·71) [n=462]
Age at introduction of other milk (months) 8·6 (5·0) [n=455] 8·4 (4·9) [n=462]
Age at introduction of regular solids (months) 8·4 (3·5) [n=455] 8·5 (3·3) [n=462]
Reported illnesses in previous 2 weeks
Fever 160 (35·2%) [n=454] 162 (35·1%) [n=462]
Cough 162 (35·7%) [n=454] 166 (35·9%) [n=462]
Diarrhoea 66 (14·5%) [n=454] 59 (12·8)% [n=462]
Diﬃ  culty breathing 31 (6·8%) [n=453] 39 (8·4%) [n=462]
Illness in ﬁ rst year
Fewer than ﬁ ve episodes of illness 223 (50·5%) [n=442] 237 (52·4%) [n=452]
Five or more episodes 219 (49·5%) [n=442] 215 (47·6%) [n=452]
Data are number (%) or mean (SD) unless otherwise indicated.
Table 2: Maternal and child characteristics at follow-up
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supplements during pregnancy were a mean 204 g 
(95% CI 27–381) heavier than controls at 2·5 years of age. 
Their mean heights did not diﬀ er, but their head 
circumferences were a mean 2·4 mm (0·6–4·3) larger, 
their chest circumferences a mean 3·2 mm (0·4–6·0) 
larger, and their hip circumferences a mean 4·0 mm 
(0·5–7·4) larger. A mean 3·3 mm diﬀ erence in waist 
circumference was not signiﬁ cant at the 5% level, and 
waist-to-hip ratios were no diﬀ erent. Mid-upper arm 
circumference was a mean 2·4 mm (1·1–3·7) larger, and 
triceps skinfold thickness a mean 2·0 mm (0·0–0·4) 
greater. Table 4 shows prenatal and postnatal diﬀ erences 
between the groups by comparing unadjusted mean 
weight, height, and head circumference at birth and at 
follow-up. Of the 203 g diﬀ erence in weight between the 
groups at follow-up, 126 g was accrued in early childhood. 
The incremental diﬀ erences in height and head 
circumference were small: 0·6 mm and 0·7 mm, 
respectively, in early childhood.
Mean systolic blood pressure was 101·9 mm Hg 
(SD 17·54, n=454) in the control group and 99·4 mm Hg 
(SD 13·68, n=460) in the intervention group. Mean 
diastolic blood pressure was 63·4 mm Hg (SD 14·71) in 
the control group and 62·05 (12·80) in the intervention 
group. Children of women who had taken multiple 
micronutrient supplements during pregnancy had 
systolic blood pressures a mean 2·5 mm Hg (95% CI 
0·47–4·55) lower than controls, but there was no 
diﬀ erence in mean diastolic blood pressure (-1·5 mm Hg 
[95% CI -3·1–0·4]).
Table 5 compares weight and height with WHO 
standards.24,25 Overall, the mean weight-for-age was 1·70, 
the mean height-for-age 2·24, and the mean weight-
for-height 0·34 Z scores below the median. The inter-
vention group showed a slightly signiﬁ cant increase in 
weight-for-age (p=0·048) and a non-signiﬁ cant increase 
in height-for-age (p=0·281), which also resulted in a 
non-signiﬁ cant diﬀ erence in weight-for-height (p=0·097). 
Deﬁ ning the cut-oﬀ s for underweight, stunting, and 
wasting as two Z scores below the medians for 
weight-for-age, height-for-age, and weight-for-height 
respectively, the overall numbers of those underweight 
were 340 (37·2%), of stunting 534 (58·4%), and of 
wasting 54 (5·9%). None of these rates were signiﬁ cantly 
diﬀ erent between the groups. Table 5 presents a detailed 
categorical breakdown of these indices, which gives the 
Control (n=455) Intervention (n=462) Diﬀ erence between groups (95% CI) Proportional increase 
over control group at 
follow-up
At birth At follow-up Increment At birth At follow-up Increment At birth At follow-up Increment
Weight (kg) 2·75
(0·41)
10·70
(1·38)
7·95
(1·28)
2·82
(0·43)
10·90
(1·54)
8·08
(1·47)
0·077
(0·02 to 0·13)
0·203
(0·01 to 0·39)
0·126
(0·05 to 0·30)
1·9%
Length/height (cm) 48·79
(3·23)
83·76
(4·68)
34·98
(5·07)
49·03
(3·14)
84·07
(4·83)
35·04
(5·14)
0·24
(–0·17 to 0·65)
0·30
(–0·31 to 0·92)
0·06
(–0·60 to 0·73)
0·4%
Head circumference 
(cm)
33·65
(2·21)
46·40
(1·43)
12·75
(2·35)
33·82
(2·24)
46·64
(1·49)
12·82
(2·38)
0·18
(–0·11 to 0·47)
0·24
(0·06 to 0·43)
0·07
(–0·23 to 0·38) 
0·5%
Data are mean (SD) unless otherwise indicated.
Table 4: Mean measurements at birth and at follow-up, with mean and proportional increments
Control 
(n=455)
Intervention 
(n=462)
Unadjusted (95% CI) Adjusted for age at 
follow-up (95% CI)
Adjusted for age at follow-up, 
sex, maternal parity, gestation 
at birth (95% CI)
Adjusted for age at follow-up, sex, 
gestation at birth, maternal weight at 
enrolment, maternal education 
(95% CI)
Weight (kg) 10·697 (1·383) 10·900(1·544) 0·203 (0·013 to 0·393)* 0·204 (0·027 to 0·381)* 0·199 (0·027 to 0·370)* 0·194 (0·038 to 0·350)*
Height (cm) 83·76 (4·68) 84·07 (4·83) 0·30 (–0·31 to 0·92) 0·31 (–0·20 to 0·82) 0·29 (–0·21 to 0·79) 0·28 (–0·17 to 0·73)
BMI (kg/m²) 15·22 (1·32) 15·39 (1·47) 0·17 (–0·01 to 0·35) 0·17 (–0·01 to 0·35) 0·17 (–0·01 to 0·34) 0·16 (–0·01 to 0·34)
Head circumference (cm) 46·40 (1·43) 46·64 (1·49) 0·24 (0·06 to 0·43)* 0·24 (0·06 to 0·43)* 0·23 (0·07 to 0·40)* 0·23 (0·07 to 0·39)*
Chest circumference (cm) 47·96 (2·26) 48·28 (2·45) 0·32 (0·01 to 0·66)* 0·32 (0·04 to 0·60)* 0·31 (0·03 to 0·58)* 0·30 (0·04 to 0·56)*
Waist circumference (cm) 46·48 (2·75) 46·81 (2·84) 0·33 (–0·03 to 0·69) 0·33 (–0·01 to 0·68) 0·33 (–0·01 to 0·67) 0·32 (–0·01 to 0·65)
Hip circumference (cm) 45·95 (2·68) 46·34 (2·94)† 0·39 (0·03 to 0·76)* 0·40 (0·05 to 0·74)* 0·39 (0·05 to 0·74)* 0·39 (0·06 to 0·71)*
Mid-upper arm 
circumference (cm)
14·18 (0·99) 14·42 (1·07) 0·24 (0·11 to 0·37)* 0·24 (0·11 to 0·37)* 0·24 (0·11 to 0·37)* 0·24 (0·11 to 0·36)*
Triceps skinfold thickness 
(mm)
6·95 (1·45) 7·15 (1·61)† 0·20 (0·00 to 0·40)* 0·20 (0·00 to 0·40)* 0·20 (–0·005 to 0·40) 0·20 (–0·004 to 0·40)
Data are mean (SD) unless otherwise indicated· BMI=body-mass index.*p<0·05 †n=461.
Table 3: Child anthropometry by allocation group, with four analytic models for diﬀ erences between group means
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impression that diﬀ erences between the groups might 
indicate a reduction in mild degrees of underweight, 
stunting and wasting in the intervention group. None of 
the diﬀ erences was signiﬁ cant. Table 5 also shows 
estimates of mean total upper arm area (TUA)20 and 
mean upper arm fat area estimate (UFE),21 both of which 
were greater in the intervention group. The upper arm 
fat percentages (UFE/TUA) were 30·1% in the control 
and 31·3% in the intervention group, a diﬀ erence 
of 1·2%.
Discussion
In our study, children aged 2·5 years whose mothers 
were given multiple micronutrients during pregnancy 
were 204 g heavier than children in the control group 
(iron and folate). Although the diﬀ erence in height was 
not signiﬁ cant, circumferences of the head, chest, hip, 
and mid-upper arm in children exposed to micronutrients 
were larger and their triceps skinfolds thicker than 
controls. Children in the micronutrient group were also 
less likely to be underweight, stunted, or wasted, although 
these ﬁ ndings were not signiﬁ cant.
We think that the only limitations of the study were 
that the sample size was insuﬃ  cient to detect small 
changes in anthropometric categories against inter-
national standards, and that ﬁ eld and budgetary con-
straints precluded more sophisticated assessments of 
body composition. Retention was satisfactory. Partici-
pants lost-to -follow-up were dispro portionately likely to 
come from a mobile, urban group who had moved out of 
the study area. The balance between potential confounders 
and the robustness of the ﬁ ndings to adjustment 
conﬁ rmed the value of blinding and random allocation. 
Anthropometrical assessments were done by only two 
observers, and systematic error should also have been 
distributed by randomisation.
One issue that might have aﬀ ected the results is that 
supplement compositions diﬀ ered in this non-placebo-
controlled trial. The supplement doses were chosen to 
match those used in other trials to optimise comparability 
and to avoid micronutrient interaction. The iron content 
of the supplements diﬀ ered (60 mg in the control and 
30 mg in the intervention group) in line with expert 
opinion,19 to avoid a possible negative inﬂ uence on zinc 
absorption (although this concern might not apply in 
practice26). Possibly, the eﬀ ects we noted were the result 
not of the addition of vitamins and minerals, but of a 
reduction in the dose of iron. The question of potential 
adverse eﬀ ects of iron supplementation in general 
remains unanswered.27
Our ﬁ ndings suggested that the gains in size at birth 
because of multiple micronutrient supplementation 
during pregnancy were maintained into childhood. They 
should, however, be kept in perspective, particularly with 
respect to childhood growth. The adjusted diﬀ erence 
of 204 g in mean weight between control and intervention 
groups represented an increment of 127 g over the 77 g 
diﬀ erence that already existed at birth—an overall 
Control group (n=453) Intervention group (n=462) Diﬀ erence (95% CI) p value
Weight-for-age Z score† –1·76 (0·98)* –1·63 (1·08)* 0·14 (0·001 to 0·27) 0·048
Height-for-age Z score† –2·28 (1·06)* –2·20 (1·12)* 0·08 (–0·06 to 0·22) 0·048
Weight-for-height Z score† –0·40 (1·05)* –0·28 (1·12)* 0·12 (–0·02 to 0·26) 0·097
Underweight†
Normal‡ 98 (21·6) 124 (26·8) .. ..
Mild underweight§ 184 (40·6) 169 (36·6) .. ..
Moderate underweight¶ 125 (27·6) 125 (27·1) .. ..
Severe weight|| 46 (10·2) 44 (9·5) .. ..
Stunting†
Normal‡ 52 (11·5) 61 (13·2) .. ..
Mild stunting§ 129 (28·5) 139 (30·1) .. ..
Moderate stunting¶ 162 (35·7) 150 (32·5) .. ..
Severe stunting|| 110 (24·3) 112 (24·2) .. ..
Wasting†
Normal‡ 331 (73·1) 354 (76·6) .. ..
Mild wasting§ 97 (21·4) 79 (17·1) .. ..
Moderate wasting¶ 19 (4·2) 25 (5·4) .. ..
Severe wasting|| 6 (1·3) 4 (0·9) .. ..
Total upper arm area (cm²)** 16·07 (2·24) 16·63 (2·50) 0·56 (0·25 to 0·87) 0·0004
Upper arm fat area estimate (cm²)†† 4·96 (1·23) 5·20 (1·43) 0·24 (0·07 to 0·41) 0·007
*Mean (SD); all other data are n (%). †Comparisons with WHO standards.24,25 ‡One Z score below the median or above.   §More than one and up to two Z scores below the median. 
¶More than two and up to three Z scores below the median. || More than three Z scores below the median. **Calculated according to equations in reference 20. ††Calculated 
according to equations in reference 21.
Table 5: Underweight, stunting, and wasting according to WHO standards, and estimates of mean upper arm total and fat areas 
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1·9% gain over the mean control group weight. Likewise, 
the postnatal increments in height and head 
circumference were only 0·6 mm and 0·7 mm, 
respectively (0·4% and 0·5% gains over the control 
group measures).
We think that the ﬁ ndings raise two key questions. 
First, were the children in the intervention group more 
healthy? Mothers’ recall of their children’s illnesses 
during infancy and the 2 weeks before the interview 
did not support this hypothesis, but it is quite possible 
that health had been aﬀ ected in more subtle ways. We 
are particularly keen to assess the children’s 
development in further follow-up studies. The 
increment in head circumference in the micronutrient 
group could indicate a diﬀ erence in brain growth and 
the potential for improved cognitive performance.28 
Equally, it might be explained by extracranial adiposity. 
A second question is whether the sustained gain in 
size is associated with physiological changes. This 
possibility is intriguing given the rapid increase in 
research into the developmental origins of health and 
adult disease.29 The small but signiﬁ cant decrease in 
systolic blood pressure in the multiple micronutrient 
group suggests it might have implications for the 
development of adult hypertension. Again, we do not 
want to over-interpret a single ﬁ nding and need to 
follow up trial cohorts.
Previously, our awareness of the burden of low 
birthweight and childhood malnutrition would have 
made us optimistic about the eﬀ ects of greater fetal, 
infant, and childhood growth on subsequent illness and 
mortality. Research over the past decade, however, raises 
questions about this assumption. We lack evidence to 
show that increasing weight at birth—and the subsequent 
tracking shown in this study—will translate into 
substantial improvements in child survival. We have 
raised the possibility of an imbalance in stillbirths and 
neonatal deaths between the allocation groups.22 The 
slight alteration to our original neonatal mortality 
ﬁ ndings is mildly reassuring, as is the similarity of 
aggregate infant mortality rates between the allocation 
groups. However, neonatal mortality remained 
40% higher in the intervention group and mortality needs 
to be examined in larger datasets.
Children such as those in our trial might show a 
predictive adaptive physiological phenotype that turns 
out to be mismatched with their later nutritional 
experience.30 In simple terms, South Asian children, 
though apparently small and thin, may have an intrinsic 
susceptibility to harmful patterns of fat deposition in 
situations of nutritional plenty.31 The children born in 
our study are generally lighter, shorter, and more wasted 
than children in aﬄ  uent populations. Has fetal multiple 
micronutrient supply had generalised eﬀ ects on growth, 
with potentially beneﬁ cial increments in lean body 
mass, or has it translated into increased adiposity? The 
biggest diﬀ erence between the two groups was in 
weight for age, and the estimates of upper arm 
composition suggest a small but signiﬁ cant increase in 
adiposity.
We are only beginning to unravel the longer-term 
eﬀ ects of increasing body mass. Its distal eﬀ ects on 
health—cognitive performance, childhood illness and 
mortality, and later blood pressure—might be beneﬁ cial, 
but we need further follow-up and larger studies to 
conﬁ rm our ﬁ ndings.
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